Addex Therapeutics to Present at the Swiss Equities Baader Conference
Addex Therapeutics (SIX/NASDAQ: ADXN), a pioneering clinical-stage biopharmaceutical company specializing in the development of novel small molecule allosteric modulators aimed at addressing neurological disorders, is gearing up for a significant presentation at the upcoming Swiss Equities Baader Conference. This year's conference will unfold in Bad Ragaz, Switzerland, and promises to be an exceptional event for sharing advancements in healthcare.
Dr. Robert Lütjens, the Head of Discovery - Biology at Addex, is set to take the stage to deliver insightful updates about the company. His presentation is both a moment of pride and an opportunity to illustrate the cutting-edge progress being made within the Central Nervous System (CNS) pipeline of Addex. Attendees can expect to gain valuable insights into the latest developments and strategic direction of the company.
Details for the Presentation
Mark your calendars for the important presentation scheduled for Friday, January 10, 2025, at 11:40 CET. The venue for this engaging session will be the Grand Resort Bad Ragaz, specifically in Room Forum 2. This presentation line-up highlights Dr. Lütjens's commitment to connecting with fellow innovators and stakeholders in the biopharmaceutical field.
One-on-One Meetings
Alongside the presentation, Dr. Lütjens will be available for one-on-one meetings throughout the conference. These sessions represent an excellent opportunity for attendees to discuss potential collaborations, insights into neurological disorder treatments, or any inquiries regarding Addex's offerings. For scheduling, interested parties should submit requests via the Baader Conference portal or reach out directly through email.
About Addex Therapeutics
Addex Therapeutics stands out in the biopharmaceutical scene with its dedicated approach to developing allosteric modulators targeting neurological disorders. Their captivating lead candidate, dipraglurant, functions as an mGlu5 negative allosteric modulator, currently under consideration for further development in areas such as brain injury recovery, including post-stroke and traumatic brain injuries. Moreover, collaboration with Indivior showcases the breadth of their pipeline, as a GABAB PAM drug candidate has been selected for development related to substance use disorders.
Innovative Research and Development
In addition to the collaborations, Addex is pursuing its independent GABAB PAM program designed for chronic cough treatment. The company has also invested in Neurosterix LLC, which explores several programs in allosteric modulation, such as M4 PAM for schizophrenia and mGlu2 NAM for mild neurocognitive disorders. Such strategic partnerships and internal programs propel Addex forward in the expansive field of neurology.
Key Contacts
For any further inquiries about Addex Therapeutics or the upcoming conference, please reach out to the following contacts:
Tim Dyer
Chief Executive Officer
Telephone: +41 22 884 15 55
Email: PR@addextherapeutics.com
Mike Sinclair
Partner, Halsin Partners
Telephone: +44 7968 022075
Email: msinclair@halsin.com
Frequently Asked Questions
What will Dr. Lütjens discuss at the conference?
Dr. Lütjens will provide a corporate update and share recent advancements from Addex’s CNS pipeline.
When is Addex's presentation scheduled?
The presentation is scheduled for Friday, January 10, 2025, at 11:40 CET.
Where is the presentation taking place?
The presentation will be held at the Grand Resort Bad Ragaz in Room Forum 2.
How can someone schedule a meeting with Dr. Lütjens?
Meetings can be scheduled via the Baader Conference portal or by emailing the company directly.
What is Addex Therapeutics known for?
Addex is known for developing innovative small molecule allosteric modulators for neurological disorders, focusing on treatments such as brain injury recovery.
